Global biotechnology firm Biogen, Inc. reported Friday a profit for the first quarter that surged 71 percent from last year, reflecting lower charges and strong double-digit revenue growth amid increased sales of multiple sclerosis drugs Tysabri and Tecfidera. However, both adjusted earnings per share and quarterly revenues missed analysts’ expectations, as Tecfidera sales growth began to slow.